TAS 301: an inhibitor of smooth muscle cell migration and proliferation; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9885087 |
| CHEMBL ID | 1377300 |
| CHEBI ID | 92970 |
| SCHEMBL ID | 725960 |
| MeSH ID | M0291519 |
| Synonym |
|---|
| BRD-K55454768-001-01-8 |
| NCGC00165914-01 |
| HSCI1_000146 |
| tas-301 |
| tas 301 |
| 3-bis-(4-methoxphenyl)methylene-2-indolinone |
| 193620-69-8 |
| S6424 |
| 3-[bis-(4-methoxy-phenyl)-methylene]-1,3-dihydro-indol-2-one |
| 3-[bis(4-methoxyphenyl)methylene]-oxindole |
| KUEYYIJXBRWZIB-UHFFFAOYSA-N |
| SCHEMBL725960 |
| CS-5012 |
| 3-[bis(4-methoxyphenyl)methylene]-1,3-dihydro-2h-indol-2-one |
| AC-35429 |
| CHEMBL1377300 |
| HY-18965 |
| AKOS024458201 |
| DTXSID80432401 |
| mfcd05865245 |
| J-690254 |
| (3r)-3-benzyl-n,n',n'-trimethyl-3-piperidinecarbohydrazide hydrochloride |
| EX-A801 |
| tas301 |
| 3-[bis(4-methoxyphenyl)methylidene]-2,3-dihydro-1h-indol-2-one |
| CHEBI:92970 |
| tas-301, >=95% (hplc), solid |
| BCP16653 |
| 3-[bis(4-methoxyphenyl)methylidene]-1h-indol-2-one |
| Q27164703 |
| FT-0700251 |
| 3-(bis(4-methoxyphenyl)methylene)indolin-2-one |
| AS-55912 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of the present study was to improve the solubility and oral bioavailability of a poorly water-soluble drug, 3-bis(4-methoxyphenyl) methylene-2-indolinone (TAS-301), by its melt-adsorption on a porous calcium silicate, Florite RE (FLR), without any solvents." | ( Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. Azuma, M; Baba, K; Houchi, H; Kinoshita, M; Minakuchi, K; Nagayasu, A; Shimooka, T; Takeichi, Y; Yamabe, K, 2002) | 0.31 |
| "3-Bis(4-Methoxyphenyl)methylene-2-indolinone (TAS-301) is a poorly water-soluble drug showing low oral bioavailability in rats and dogs." | ( Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Azuma, M; Baba, K; Houchi, H; Kinoshita, M; Minakuchi, K; Nagayasu, A; Yamabe, K, 2003) | 0.32 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The area under the plasma concentration-time curve (AUC) and peak concentration (C(max)) values of the drug after dosing the melt-adsorbed product were significantly greater than those after dosing the drug crystals." | ( Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. Azuma, M; Baba, K; Houchi, H; Kinoshita, M; Minakuchi, K; Nagayasu, A; Shimooka, T; Takeichi, Y; Yamabe, K, 2002) | 0.31 |
| Class | Description |
|---|---|
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 15.8489 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 5.0119 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||